Long-term efficacy and safety of Control-IQ technology in younger children with type 1 diabetes in Italy (2020–2023): a longitudinal multicentre real-world study
Abstract
Background: Automated insulin delivery (AID) systems have demonstrated significant improvements in glycemic control in children and adults with type 1 diabetes, but long-term real-world data in preschool-aged children remain limited, particularly in Europe, where Control-IQ is not approved for children under 6 years. This study aimed to evaluate the long-term effectiveness and safety of the t:slim X2 insulin pump with Control-IQ technology in children aged 0.5-5 years compared with those aged 6-10 years in a real-world multicenter Italian cohort. Methods: In this longitudinal, observational study conducted from 2020 to 2023, data were collected from 32 Italian centers on children
Fields of Study & Subjects
Diabetes Management and Research
Mobile Health and mHealth Applications
Pancreatic function and diabetes
Publication details
- Journal / source
- EClinicalMedicine
- Publisher
- Elsevier BV
- Volume
- 93
- Pages
- 103829–103829
- Publication date
- 1 March 2026
- Language
- EN